KFAS
GILD icon

Keating Financial Advisory Services’s Gilead Sciences GILD Stock Holding History

Keating Financial Advisory Services’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$352K Sell
2,783
-577
-17% -$76K 0.05% 250
2026
Q1 		$468K Sell
3,360
-4,536
-57% -$635K 0.08% 181
2025
Q4 		$969K Buy
+7,896
New +$960K 0.13% 131

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Keating Financial Advisory Services's GILD Position: Q2 2026 in Review

Keating Financial Advisory Services reduced its Gilead Sciences (GILD) stake by 17% in Q2 2026, selling an estimated $76K and leaving 2,783 shares worth $352K. The position accounts for 0.05% of the portfolio, ranked #250.

Keating Financial Advisory Services first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $969K in Q4 2025. 2,273 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Keating Financial Advisory Services held 2,783 shares of Gilead Sciences worth $352K as of Q2 2026.
  • Keating Financial Advisory Services sold 577 Gilead Sciences shares in Q2 2026, an estimated $76K.
  • Gilead Sciences made up 0.05% of Keating Financial Advisory Services's portfolio in Q2 2026, its #250 holding.
  • Keating Financial Advisory Services first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • Keating Financial Advisory Services's Gilead Sciences position peaked at $969K in Q4 2025.
  • 2,273 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.